Novo Nordisk and generic manufacturers face sluggish GLP-1 market in India

Demand for GLP-1 weight-loss medications in India remains lower than anticipated despite the entry of generic alternatives. It is unclear whether this reflects price sensitivity, lack of market penetration, or cultural factors, but the trend suggests a significant barrier to the rapid adoption of obesity treatments in the region.